Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback